Clinical trial

Microdosing Psychedelics to Improve Mood

Rotem PetrankerCompletedPhase 2Started Jul 15, 202339 enrolledCanadaNCT05259943

Abstract

This trial aims to examine the safety and efficacy of small (2mg) sub-hallucinogenic doses of psilocybin in people with Major Depressive Disorder.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

PsychedelicsCreativityMindfulnessMajor Depressive Disorder

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.

Publications from this trial

ArticlePsilocybin

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.

Beidas Z, Ragnhildstveit A, Blackman A +9

Europe PMC2026

Related research

ArticlePsilocybin

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Shah K, Trivedi C, Kamrai D +2

Europe PMC2022

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023

ArticlePsilocybin

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways.

Yao S, Wei C, Lin H +5

Europe PMC2022